SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

With regards to his pioglitazone use, he had no history of heart failure, and his ALT level was acceptable at the time of discharge at 25 U/L. Signs and symptoms of heart failure were reviewed with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most adults with type 2 diabetes receiving an ...

Severe Hypoglycemia Ups Cardiovascular Risk in Diabetes Two studies demonstrate no difference versus placebo for saxagliptin, alogliptin. For patients with type 2 diabetes, treatment with the ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

The American College of Physicians issued new guidelines for Type 2 diabetes treatment, which for the first time recommends the use of GLP-1s and another class of diabetes drugs called SGLT-2s ...

(HealthDay News) — The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with an increased risk of hospitalization for community-acquired pneumonia, according to a study published in ...